208
Participants
Start Date
August 31, 2001
Primary Completion Date
August 31, 2003
Study Completion Date
August 31, 2003
activated recombinant human factor VII
120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
activated recombinant human factor VII
60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
placebo
Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
Novo Nordisk Investigational Site, Camperdown
Novo Nordisk Investigational Site, Heidelberg
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, Essen
Novo Nordisk Investigational Site, Valencia
Novo Nordisk Investigational Site, Barakaldo
Novo Nordisk Investigational Site, Vancouver
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, Québec
Novo Nordisk Investigational Site, Toronto
Novo Nordisk Investigational Site, Clichy
Novo Nordisk Investigational Site, Barcelona
Novo Nordisk Investigational Site, Gothenburg
Novo Nordisk Investigational Site, Stockholm
Novo Nordisk Investigational Site, Birmingham
Novo Nordisk Investigational Site, Edinburgh
Novo Nordisk Investigational Site, Leeds
Novo Nordisk Investigational Site, London
Lead Sponsor
Novo Nordisk A/S
INDUSTRY